By A Mystery Man Writer
Cancers, Free Full-Text
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial, Breast Cancer Research
CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials - ScienceDirect
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial
Frontiers Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial - ScienceDirect
Postoperative dose-dense sequential versus concomitant
PDF) CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results, BMC Cancer
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial - ScienceDirect
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. - Abstract - Europe PMC
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial - ScienceDirect
Cancers, Free Full-Text
Cancers, Free Full-Text